middle.news

Orthocell Breaks Records and Launches Remplir™ in US Nerve Repair Market

9:08am on Wednesday 9th of July, 2025 AEST Healthcare
Read Story

Orthocell Breaks Records and Launches Remplir™ in US Nerve Repair Market

9:08am on Wednesday 9th of July, 2025 AEST
Key Points
  • Record FY2025 revenue of A$9.19 million, up 35.8% year-on-year
  • First US commercial use of Remplir™ after FDA 510(k) clearance in April 2025
  • Established US distributor network across 25 states with 14 specialist partners
  • Regulatory approvals secured in Hong Kong, Thailand, Canada, and Brazil
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Orthocell (ASX:OCC)
OPEN ARTICLE